Company Profile - About Us - 乐普心泰医疗公司 
Global
CN EN

Concerned about Structural Heart Diseases
Facilitate Patients to Build a Healthy Lifestyle

Company Profile

As a pioneer specializing in interventional medical devices targeting structural heart diseases and a large China-based supplier of CHD occluders and related procedural accessories, we are committed to providing safe, effective and innovative medical solutions.

We are engaged in the research and development, manufacturing and marketing of interventional medical devices targeting structural heart diseases. With 50 products available on the market and under development, our product line covers CHD occluders for the interventional treatment of CHDs, LAA occluders and PFO occluders for the prevention and treatment of cardioembolic stroke, and interventional valves; hence, all-round solutions are available for the interventional therapy of structural heart diseases. Our products have been sold in more than 30 countries.

 

We are a strong player in research and development, with a number of innovative products with independent intellectual property rights, taking the lead in the research and development of biodegradable technologies. In 2009, the project of "development and clinical application of interventional treatment series occluder for defective congenital heart" was awarded “Second Prize of National Science and Technology Progress Award". As of the end of April 2022, the Company has been granted 228 registered patents.”

 

We will keep on investing in research and development, and developing novel products and technologies to benefit more patients with structural heart diseases, thereby contributing to the cause of human health.

  1. Products available on the market and under development

  2. A number of patent certifications

  3. +

    Hospitals covered

  4. +

    countries where the products are marketed

Corporate Culture

  1. Our Mission

    Shape better lives with care from “heart”

Social Responsibilities

ScienTech Medical Technology - Far more than care from “heart”: making the warmth of love and healthy companionship accessible to every family

- For patients, we are committed to providing safe, effective and innovative medical solutions

- For doctors and nurses, we live up to every piece of trust and guard each heroic act

- For employees, we guarantee that every ScienTech people can grow with Scientech

- For the society, we are devoted to the public welfare undertakings, and give back to society in different ways

 

In July 2009, we donated to build the Rehabilitation Center of the Public Health Center of Jiangfeng Town
In 2013, we went to Ali to visit the children with CHDs
In 2017, we donated 30 occluders to Songjiang Women’s Federation and China Children and Teenagers' Fund Songjiang Branch
In 2017, we went to Children's Hospital of Soochow University on the World Heart Day to visit and deliver love to the patients

In April 2022, we together with IPE Center, a subsidiary of Lepu Medical, donated shelter laboratories and equipment with a worth of RMB10 million to Minhang District when the COVID-19 epidemic broke out in Shanghai. Meanwhile, we have guaranteed the supply of antigen detection reagent products to various areas in Songjiang District and Minhang District to ensure the smooth progress of residents' antigen self-testing work

 

Great undertakings have small beginnings, and difficult tasks are tackled from where it's easy.

ScienTech Medical Technology will keep on striving for the upgrading of human health undertakings.

Milestones

  1. In 1994

    We were incorporated in Shanghai in May

  2. In 2001

    Utilizing our VSD occluders, the first "VSD occluder implantation" surgery was successfully operated in China

  3. In 2003

    Our CHD occluders under the trademark of MemoPart® were approved by the NMPA for commercial use

  1. In 2008

    We became a wholly-owned subsidiary of Lepu Medical

  2. In 2009

    Our interventional treatment series occluder for defective congenital heart disease was awarded "Second Prize of National Science and Technology Progress Award"

  3. In 2012

    Our occluder under the trademark of MemoPart® received CE Mark

  1. In 2018

    Utilizing our occluders, the first "fully biodegradable occluder implantation"surgery was conducted successfully in China

  2. In 2020

    Our MemoCarna® ASD Occluder III (Oxide Coating) and MemoLefort® LAA Closure Occluder I were approved by the NMPA for commercial use

  3. In 2021

    Our MemoCarna® PDA Occluder III (Oxide Coating) was approved by the NMPA for commercial use. Our MemoSorb® PFO Occluder II (Biodegradable), MemoSorb® ASD Occluder IV (Biodegradable) and SinoCrown™ Transcatheter aortic valve replacement ("TAVR") system were brought into clinical trials

  1. In 2022

    MemoSorb️®Biodegradable VSD Occluder System and GruiserGruiser™Occluder Interventional Delivery System were approved by the NMPA for commerical use

In 1994

We were incorporated in Shanghai in May

In 2001

Utilizing our VSD occluders, the first "VSD occluder implantation" surgery was successfully operated in China

In 2003

Our CHD occluders under the trademark of MemoPart® were approved by the NMPA for commercial use

In 2008

We became a wholly-owned subsidiary of Lepu Medical

In 2009

Our interventional treatment series occluder for defective congenital heart disease was awarded "Second Prize of National Science and Technology Progress Award"

In 2012

Our occluder under the trademark of MemoPart® received CE Mark

In 2018

Utilizing our occluders, the first "fully biodegradable occluder implantation"surgery was conducted successfully in China

In 2020

Our MemoCarna® ASD Occluder III (Oxide Coating) and MemoLefort® LAA Closure Occluder I were approved by the NMPA for commercial use

In 2021

Our MemoCarna® PDA Occluder III (Oxide Coating) was approved by the NMPA for commercial use. Our MemoSorb® PFO Occluder II (Biodegradable), MemoSorb® ASD Occluder IV (Biodegradable) and SinoCrown™ Transcatheter aortic valve replacement ("TAVR") system were brought into clinical trials

In 2022

MemoSorb️®Biodegradable VSD Occluder System and GruiserGruiser™Occluder Interventional Delivery System were approved by the NMPA for commerical use

Worldwide Footprint

With products exported to Brazil, Italy, Russia and other countries, we have established a three-tier quality control system based on domestic medical device laws and regulations, EU medical device laws and regulations as well as the relevant international quality authentication standard.



Copyright © 2021, Scientech Medical. All rights reserved.沪公网安备31011702008238号沪ICP备2021017431号